ACM
PRCT icon

Accent Capital Management’s Procept Biorobotics PRCT Stock Holding History

Accent Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$8.05K – 334
2024
Q4 		$8.05K Sell
100
-88
-47% -$7.52K ﹤0.01% 155
2024
Q3 		$15.1K Buy
+188
New +$13.4K 0.01% 149

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Accent Capital Management's PRCT Position: Q1 2025 in Review

Accent Capital Management sold out of Procept Biorobotics (PRCT) in Q1 2025, closing a stake of 100 shares — an estimated $8.05K sold.

Accent Capital Management first reported a position in PRCT in Q3 2024 and held it in 2 quarters. The position peaked at $15.1K in Q3 2024. 279 funds tracked by Wall St. Rank hold PRCT as of Q1 2025.

  • Accent Capital Management reported no remaining Procept Biorobotics position as of Q1 2025 after selling out during the quarter.
  • Accent Capital Management sold 100 Procept Biorobotics shares in Q1 2025, an estimated $8.05K.
  • Accent Capital Management first reported a position in Procept Biorobotics in Q3 2024 and held it in 2 quarters.
  • Accent Capital Management's Procept Biorobotics position peaked at $15.1K in Q3 2024.
  • 279 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2025.

Based on Accent Capital Management's 13F filing for Q1 2025, filed 9 May 2025.